286 related articles for article (PubMed ID: 25412710)
1. Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology.
Fumagalli D; Blanchet-Cohen A; Brown D; Desmedt C; Gacquer D; Michiels S; Rothé F; Majjaj S; Salgado R; Larsimont D; Ignatiadis M; Maetens M; Piccart M; Detours V; Sotiriou C; Haibe-Kains B
BMC Genomics; 2014 Nov; 15(1):1008. PubMed ID: 25412710
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series.
Picornell AC; Echavarria I; Alvarez E; López-Tarruella S; Jerez Y; Hoadley K; Parker JS; Del Monte-Millán M; Ramos-Medina R; Gayarre J; Ocaña I; Cebollero M; Massarrah T; Moreno F; García Saenz JA; Gómez Moreno H; Ballesteros A; Ruiz Borrego M; Perou CM; Martin M
BMC Genomics; 2019 Jun; 20(1):452. PubMed ID: 31159741
[TBL] [Abstract][Full Text] [Related]
3. Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue.
Jovanović B; Sheng Q; Seitz RS; Lawrence KD; Morris SW; Thomas LR; Hout DR; Schweitzer BL; Guo Y; Pietenpol JA; Lehmann BD
BMC Cancer; 2017 Apr; 17(1):241. PubMed ID: 28376728
[TBL] [Abstract][Full Text] [Related]
4. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
[TBL] [Abstract][Full Text] [Related]
5. An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk.
Yau C; Sninsky J; Kwok S; Wang A; Degnim A; Ingle JN; Gillett C; Tutt A; Waldman F; Moore D; Esserman L; Benz CC
Breast Cancer Res; 2013; 15(5):R103. PubMed ID: 24172169
[TBL] [Abstract][Full Text] [Related]
6. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
7. Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression.
Kwan ML; Kroenke CH; Sweeney C; Bernard PS; Weltzien EK; Castillo A; Factor RE; Maxfield KS; Stijleman IJ; Kushi LH; Quesenberry CP; Habel LA; Caan BJ
BMC Cancer; 2015 Apr; 15():278. PubMed ID: 25884832
[TBL] [Abstract][Full Text] [Related]
8. CORRELATION BETWEEN CLINICAL PATHOLOGY OF LUMINAL B BREAST CANCER AND DETERMINATION OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR AND HER2 EXPRESSION COMBINED WITH NUCLEAR MORPHOLOGY.
Yin D; Wang YL; Wang YF; Yang L; Zhang L; Tang C; Xie W; Ma Y
J Biol Regul Homeost Agents; 2015; 29(3):579-87. PubMed ID: 26403396
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of breast cancer using pathway profiles.
Tian F; Wang Y; Seiler M; Hu Z
BMC Med Genomics; 2014 Jul; 7():45. PubMed ID: 25041817
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
11. Molecular subtyping of breast cancer intrinsic taxonomy with oligonucleotide microarray and NanoString nCounter.
Chen YJ; Huang CS; Phan NN; Lu TP; Liu CY; Huang CJ; Chiu JH; Tseng LM; Huang CC
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34387660
[TBL] [Abstract][Full Text] [Related]
12. Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer.
Roepman P; Horlings HM; Krijgsman O; Kok M; Bueno-de-Mesquita JM; Bender R; Linn SC; Glas AM; van de Vijver MJ
Clin Cancer Res; 2009 Nov; 15(22):7003-11. PubMed ID: 19887485
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
Wu JR; Zhao Y; Zhou XP; Qin X
Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
[TBL] [Abstract][Full Text] [Related]
14. HER2 expression is a strong independent predictor of nodal metastasis in breast cancer.
Ahmed AR
J Egypt Natl Canc Inst; 2016 Dec; 28(4):219-227. PubMed ID: 27756653
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Soliman H; Wagner S; Flake DD; Robson M; Schwartzberg L; Sharma P; Magliocco A; Kronenwett R; Lancaster JM; Lanchbury JS; Gutin A; Gradishar W
Ann Surg Oncol; 2020 Mar; 27(3):765-771. PubMed ID: 31907749
[TBL] [Abstract][Full Text] [Related]
17. Using microarray-based subtyping methods for breast cancer in the era of high-throughput RNA sequencing.
Pedersen CB; Nielsen FC; Rossing M; Olsen LR
Mol Oncol; 2018 Dec; 12(12):2136-2146. PubMed ID: 30289602
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer.
Park SY; Kim HM; Koo JS
Breast Cancer Res Treat; 2015 Feb; 149(3):727-41. PubMed ID: 25667103
[TBL] [Abstract][Full Text] [Related]
19. Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis.
Wu YM; Hu W; Wang Y; Wang N; Gao L; Chen ZZ; Zheng WQ
Breast Cancer Res Treat; 2013 Aug; 141(1):23-32. PubMed ID: 23933801
[TBL] [Abstract][Full Text] [Related]
20. Identification of transcriptional subtypes in lung adenocarcinoma and squamous cell carcinoma through integrative analysis of microarray and RNA sequencing data.
Fauteux F; Surendra A; McComb S; Pan Y; Hill JJ
Sci Rep; 2021 Apr; 11(1):8709. PubMed ID: 33888829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
